File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Are herbal medicinal products less teratogenic than Western pharmaceutical products?

TitleAre herbal medicinal products less teratogenic than Western pharmaceutical products?
Authors
KeywordsHerbal medicine
Pregnancy
Teratogenicity
Issue Date2002
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/aps/index.html
Citation
Acta Pharmacologica Sinica, 2002, v. 23 n. 12, p. 1169-1172 How to Cite?
AbstractAIM: To determine the use and teratogenicity of herbal medicinal products (HMP). METHODS: A retrospective study was conducted in a University hospital to compare the difference in the pattern of use and fetal outcomes between pregnant women who took HMP and Western pharmaceutical products (WPP). RESULTS: From 1995 Jan to 2001 Dec, 61 and 372 women took HMP and WPP one month before or during their current pregnancies respectively. There was an increase in the prevalence of pregnant women who took HMP from 0 % in 1995 to 0.8 % in 2001. Among HMP users, 51.6 %, 82.8 % and 58.6 % of them had low monthly family income (<15 000), low education level (secondary education or below) and were unemployed respectively. In comparison to WPP, pregnant women used smaller number of HMP (1.4 vs 3.0, P<0.01) at a later gestation (4.8 weeks vs 3.1 weeks, P<0.01) and within a shorter duration (11.1 d vs 47.9 d, P<0.01). The prevalence of congenital fetal abnormalities in the group of women who took HMP (3.3 %) was not significantly higher than that who took WPP (0.8 %). There were no and two abnormal fetal karyotypes in the former and latter group respectively. No and ten women in the former and latter group underwent termination of pregnancy for anxiety respectively. The proportions of silent miscarriage in the former and latter group were similar (6.6 % vs 5.4 %). CONCLUSION: Pregnant users of HMP were from lower socio-economical status. There was no significant difference in the teratogenicity between HMP and WPP.
Persistent Identifierhttp://hdl.handle.net/10722/180757
ISSN
2023 Impact Factor: 6.9
2023 SCImago Journal Rankings: 1.882
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLeung, KYen_US
dc.contributor.authorLee, YPen_US
dc.contributor.authorChan, HYen_US
dc.contributor.authorLee, CPen_US
dc.contributor.authorTang, MHYen_US
dc.date.accessioned2013-01-28T01:42:31Z-
dc.date.available2013-01-28T01:42:31Z-
dc.date.issued2002en_US
dc.identifier.citationActa Pharmacologica Sinica, 2002, v. 23 n. 12, p. 1169-1172en_US
dc.identifier.issn1671-4083en_US
dc.identifier.urihttp://hdl.handle.net/10722/180757-
dc.description.abstractAIM: To determine the use and teratogenicity of herbal medicinal products (HMP). METHODS: A retrospective study was conducted in a University hospital to compare the difference in the pattern of use and fetal outcomes between pregnant women who took HMP and Western pharmaceutical products (WPP). RESULTS: From 1995 Jan to 2001 Dec, 61 and 372 women took HMP and WPP one month before or during their current pregnancies respectively. There was an increase in the prevalence of pregnant women who took HMP from 0 % in 1995 to 0.8 % in 2001. Among HMP users, 51.6 %, 82.8 % and 58.6 % of them had low monthly family income (<15 000), low education level (secondary education or below) and were unemployed respectively. In comparison to WPP, pregnant women used smaller number of HMP (1.4 vs 3.0, P<0.01) at a later gestation (4.8 weeks vs 3.1 weeks, P<0.01) and within a shorter duration (11.1 d vs 47.9 d, P<0.01). The prevalence of congenital fetal abnormalities in the group of women who took HMP (3.3 %) was not significantly higher than that who took WPP (0.8 %). There were no and two abnormal fetal karyotypes in the former and latter group respectively. No and ten women in the former and latter group underwent termination of pregnancy for anxiety respectively. The proportions of silent miscarriage in the former and latter group were similar (6.6 % vs 5.4 %). CONCLUSION: Pregnant users of HMP were from lower socio-economical status. There was no significant difference in the teratogenicity between HMP and WPP.en_US
dc.languageengen_US
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/aps/index.htmlen_US
dc.relation.ispartofActa Pharmacologica Sinicaen_US
dc.subjectHerbal medicine-
dc.subjectPregnancy-
dc.subjectTeratogenicity-
dc.subject.meshDown Syndrome - Etiologyen_US
dc.subject.meshDrug Combinationsen_US
dc.subject.meshDrugs, Chinese Herbal - Adverse Effects - Isolation & Purificationen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshPharmaceutical Preparations - Adverse Effectsen_US
dc.subject.meshPlants, Medicinalen_US
dc.subject.meshPregnancyen_US
dc.subject.meshPregnancy Outcomeen_US
dc.subject.meshRetrospective Studiesen_US
dc.titleAre herbal medicinal products less teratogenic than Western pharmaceutical products?en_US
dc.typeArticleen_US
dc.identifier.emailTang, MHY: mhytang@hkucc.hku.hken_US
dc.identifier.authorityTang, MHY=rp01701en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid12466056-
dc.identifier.scopuseid_2-s2.0-0036902384en_US
dc.identifier.hkuros79017-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0036902384&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume23en_US
dc.identifier.issue12en_US
dc.identifier.spage1169en_US
dc.identifier.epage1172en_US
dc.identifier.isiWOS:000179779100017-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLeung, KY=8247106900en_US
dc.identifier.scopusauthoridLee, YP=15033545100en_US
dc.identifier.scopusauthoridChan, HY=7403402562en_US
dc.identifier.scopusauthoridLee, CP=7410149538en_US
dc.identifier.scopusauthoridTang, MHY=8943401300en_US
dc.identifier.issnl1671-4083-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats